Electromed Inc has formed a bronchiectasis advisory board composed of three renowned experts in pulmonary medicine, according to a company announcement.

The bronchiectasis advisory board will serve as a key strategic resource to advance disease awareness and help guide the development of clinical research plans and future airway clearance therapy innovations.

The members of the board include:

  • Chad Marion, DO, PhD, is an Assistant Professor and Associate Director of the Adult Cystic Fibrosis Program of Medicine at Wake Forest Baptist Health and board-certified in Internal Medicine and Pulmonary Disease.
  • Peadar Noone, MD, FCCP, FRCPI, DCH, MRCGP, is a Professor of Medicine and Medical Director for the University of North Carolina Center for Bronchiectasis Care
  • Anne O’Donnell, MD, is the Professor of Medicine and Chief, Division of Pulmonary, Critical Care, and Sleep Medicine at Georgetown University Medical Center.

“Electromed is committed to engaging clinicians, payers and patients with evidence-based information to advance bronchiectasis awareness,” commented Kathleen Skarvan, President and Chief Executive Officer of Electromed. “We are thrilled to have Dr. Noone, Dr. O’Donnell, and Dr. Marion – global thought leaders in the field of pulmonary medicine – join the Electromed bronchiectasis advisory board.

“In collaboration with these distinguished physicians, Electromed will continue to focus on educating the healthcare community on the effectiveness and value of airway clearance therapy in improving patients’ quality of life and reducing bronchiectasis healthcare utilization and associated costs.”